Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial.

Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
JAMA The Journal of the American Medical Association (Impact Factor: 35.29). 12/2002; 288(18):2282-92.
Source: PubMed


Hormone administration to elderly individuals can increase lean body mass (LBM) and decrease fat, but interactive effects of growth hormone (GH) and sex steroids and their influence on strength and endurance are unknown.
To evaluate the effects of recombinant human GH and/or sex steroids on body composition, strength, endurance, and adverse outcomes in aged persons.
A 26-week randomized, double-blind, placebo-controlled parallel-group trial in healthy, ambulatory, community-dwelling US women (n = 57) and men (n = 74) aged 65 to 88 years recruited between June 1992 and July 1998.
Participants were randomized to receive GH (starting dose, 30 micro g/kg, reduced to 20 micro g/kg, subcutaneously 3 times/wk) + sex steroids (women: transdermal estradiol, 100 micro g/d, plus oral medroxyprogesterone acetate, 10 mg/d, during the last 10 days of each 28-day cycle [HRT]; men: testosterone enanthate, biweekly intramuscular injections of 100 mg) (n = 35); GH + placebo sex steroid (n = 30); sex steroid + placebo GH (n = 35); or placebo GH + placebo sex steroid (n = 31) in a 2 x 2 factorial design.
Lean body mass, fat mass, muscle strength, maximum oxygen uptake (VO(2)max) during treadmill test, and adverse effects.
In women, LBM increased by 0.4 kg with placebo, 1.2 kg with HRT (P =.09), 1.0 kg with GH (P =.001), and 2.1 kg with GH + HRT (P<.001). Fat mass decreased significantly in the GH and GH + HRT groups. In men, LBM increased by 0.1 kg with placebo, 1.4 kg with testosterone (P =.06), 3.1 kg with GH (P<.001), and 4.3 kg with GH + testosterone (P<.001). Fat mass decreased significantly with GH and GH + testosterone. Women's strength decreased in the placebo group and increased nonsignificantly with HRT (P =.09), GH (P =.29), and GH + HRT (P =.14). Men's strength also did not increase significantly except for a marginally significant increase of 13.5 kg with GH + testosterone (P =.05). Women's VO(2)max declined by 0.4 mL/min/kg in the placebo and HRT groups but increased with GH (P =.07) and GH + HRT (P =.06). Men's VO(2)max declined by 1.2 mL/min/kg with placebo and by 0.4 mL/min/kg with testosterone (P =.49) but increased with GH (P =.11) and with GH + testosterone (P<.001). Changes in strength (r = 0.355; P<.001) and in VO(2)max (r = 0.320; P =.002) were directly related to changes in LBM. Edema was significantly more common in women taking GH (39% vs 0%) and GH + HRT (38% vs 0%). Carpal tunnel symptoms were more common in men taking GH + testosterone (32% vs 0%) and arthralgias were more common in men taking GH (41% vs 0%). Diabetes or glucose intolerance occurred in 18 GH-treated men vs 7 not receiving GH (P =.006).
In this study, GH with or without sex steroids in healthy, aged women and men increased LBM and decreased fat mass. Sex steroid + GH increased muscle strength marginally and VO( 2)max in men, but women had no significant change in strength or cardiovascular endurance. Because adverse effects were frequent (importantly, diabetes and glucose intolerance), GH interventions in the elderly should be confined to controlled studies.

Download full-text


Available from: John Sorkin,
  • Source
    • "The concept of somatopause indicates the potential link between the decline in GH and IGF-I levels and frailty during aging (Giordano et al. 2008). In addition, this decline has been also implicated in the age-associated changes observed in several physiological functions (Muller et al. 2002; Vitiello et al. 2006) Growth hormone decrease has been widely documented for its relevancy in the aging process, and as potential candidate for replacement therapies, both in humans and animals (Baeza et al. 2008; Blackman et al. 2002; Cuesta et al. 2011; Vitiello et al. 2006). Several beneficial results obtained by our group with GH therapy on different animal models strongly support this fact (Castillo et al. 2005; Cuesta et al. 2011; Forman et al. 2011; Kireev et al. 2007a,b). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammation is related to several pathological processes. The aim of this study was to investigate the protein expression of the different subunits of the nuclear factor Kappa b (NFkBp65, p50, p105, p52, p100) and the protein expressions of IkB beta and alpha on hearts from a murine model of accelerated aging (SAM model) by Western Blot. In addition, the translocation of some isoforms of NFkB from cytosol to nuclei (NFkB p65, p50, p52) and ATP level content were studied. In addition we investigated the effect of the chronic administration of Growth Hormone (GH) on these age-related parameters. SAMP8 and SAMR1 mice of 2 and 10 months of age were used (n=30). Animals were divided into five experimental groups: 2 old untreated (SAMP8/SAMR1), 2 young control (SAMP8/SAMR1) and one GH treated-old group (SAMP8). Age-related changes were found in the studied parameters. We were able to see decreases of ATP levels contents and the translocation of the nuclear factor kappa B p50, p52 and p65 from cytosol to nuclei in old SAMP8 mice together with a decrease of IKB proteins. However p100 and p105 did not show differences with aging. No significant changes were recorded in SAMR1 animals. GH treatment showed beneficial effects in old SAMP8 mice inducing an increase in ATP levels and inhibiting the translocation of some NFkB subunits such as p52. Our results supported the relation of NFkB activation with enhanced apoptosis and pro-inflammatory status in old SAMP8 mice and suggested a selective beneficial effect of the GH treatment, which was able to partially reduce the incidence of some deleterious changes in the heart of those mice.
    Experimental Gerontology 11/2015; DOI:10.1016/j.exger.2015.11.005 · 3.49 Impact Factor
  • Source
    • "The drug used was testosterone enanthate (Sheffield- Moore et al. 2011; Page et al. 2005; Ferrando et al. 2003; Blackman et al. 2002), oxandrolone (Schroeder et al. 2005; Schroeder et al. 2004; Schroeder et al. 2003a), testosterone undecanoate (Emmelot-Vonk et al. 2008; Wittert et al. 2003), oxymetholone (Schroeder et al. 2003b), and Androgel (Kenny et al. 2010). The administration method used was oral (6 articles), injection (4 articles), and transdermal gel (1 article). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to evaluate the effects of steroid anabolic androgenic hormones use on lean mass gain in elderly men through a systematic review with a meta-analysis of randomized controlled studies. We systematically searched PubMed database until 4th October 2013. We included randomized placebo-controlled trials (RCT) that studied testosterone replacement therapy in men over 60 years of age, with total testosterone levels ≤550 ng/dl, observing gains in weight, lean mass tissue and fat mass as outcome. We excluded duplicated studies, studies which mixed men and women, and studies using weak androgens such as dehydroepiandrosterone or androstenedione. The initial search yielded 2681 articles, of which 26 were selected for full text analysis. In the end, 11 studies were included. However, 3 studies were not included in the meta-analysis. Meta-analysis showed that mean weight increased (lean mass), ranging from 1.65 (95 % CI, 1.61–1.69) to 6.20 (95 % CI, 5.22–7.18) kg, although it was heterogeneous (I 2 = 98 %). Effect estimate was 3.59 [2.38–4.81]. Androgen therapy decreased fat mass; effect estimate was −1.78 [−2.57, −0.99] that analysis had also a high level of heterogeneity (I 2 = 81 %). The results suggest that testosterone replacement therapy is able to increase muscle mass in elderly men and that is affected by the time that the treatment is carried out and the method of administration of the drug.
    Journal of the American Aging Association 02/2015; 37(1):9742. DOI:10.1007/s11357-014-9742-0 · 3.39 Impact Factor
  • Source
    • "Whether high GSK3 activity and/or inactivation of PI3K/Akt in peripheral blood cells increase CVD or cancer risk or poor outcome of cancer remains to be investigated. The study first elucidates how GSK3 activity is released and how cells become insensitive as well as die early, explaining why the body cells reduce use of the hormones with age (Denckla 1974; Blackman et al. 2002). Overstimulation-caused PI3K/Akt/GSK3 insensitivity and high GSK3 activity are the fundamentals to propose the alternative death hormones hypothesis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aging is linked to decrease of the body cell use of growth hormone (GH) and thyroxine, whereas the decrease is via “death hormones” inhibition? This study proposes different viewpoints. Since interleukin 17 receptor C (IL17RC) is highly expressed in tissues from age-related macular degeneration (AMD) patients, IL17RC signaling pathways are explored to evaluate Wnts/vascular endothelial growth factor (VEGF) expression and complement activity, which are pathological factors in AMD. IL17RC overexpression or VEGF treatment was performed in two cell lines for up to two-day. Real-time Quantitative PCR, confocal microscopy, immune-blot, MTT assay, etc. measured downstream effects. IL17RC overexpression increases Wnts and VEGF that forms complexes with Wnt-signaling components. VEGF or the Wnt-signaling components interacting with C3 suggests alternative complement pathway activation. Moreover, IL17RC-overexpressed cells or VEGF-treated cells for two-day, which is overstimulation, increase PI3K/Akt/GSK3 insensitivity and GSK3 activity, and decrease growth/survival. High GSK3 activity associates with many chronic diseases including type II Diabetes. This study shows high GSK3 activity can result from PI3K/Akt overstimulation. Type II Diabetes shows insulin resistance that the body cells decrease insulin use. Possessing little sensitive PI3K/Akt for receptor activation, cells after overstimulation, although live, hardly respond to PI3K/Akt activators including GH, thyroxine and insulin. These results suggest an alternative explanation of the body cells declining hormone use since various kinds of cell signaling-induced overstimulation events almost always linked to PI3K/Akt, increase with age. Playing pathological roles in senescence and diseases, overstimulation eventually generates health problems. Electronic supplementary material The online version of this article (doi:10.1186/2193-1801-3-356) contains supplementary material, which is available to authorized users.
    SpringerPlus 07/2014; 3(1):356. DOI:10.1186/2193-1801-3-356
Show more